Unlike SaaS, hard tech lacks standardized metrics. Founders must demonstrate momentum across three pillars: hiring exceptional, domain-expert talent (people); achieving tangible technical milestones (product); and securing customer commitments like LOIs or contracts (traction) to prove viability.

Unlike tech investing, where a single power-law outlier can return the entire fund, biotech wins are smaller in magnitude. This dynamic forces biotech VCs to prioritize a higher success rate across their portfolio rather than solely hunting for one massive unicorn.

To raise capital, biotechs need specific clinical data. Raj Devraj specifies the three essential components investors look for: 1) confirmation of good drug exposure in humans, 2) a favorable early safety profile, and 3) biomarker data that provides proof of the drug's biological mechanism. Lacking any of these makes fundraising significantly harder.

The static size of a Total Addressable Market (TAM) is a misleading metric for big ideas. A better evaluation framework focuses on two questions: Will the product's innovation cause the existing TAM to grow multiple times over? Can the company layer on additional, new TAMs over its lifetime?

Raj Devraj simplifies biotech venture evaluation into a four-part framework: scientific viability ("Will it work?"), market viability ("Will it sell?"), feasibility ("Can I do it in my lifetime?"), and execution capability ("Do I have the team?"). This provides a comprehensive yet concise due diligence checklist for early-stage opportunities.

Massive opportunities are built on a three-legged framework, starting with an undeniable market gap. This gap must be an unequivocal data point, not a manufactured projection. Only after identifying this 'force of nature' can a great team be assembled, which then makes securing funding significantly easier.

When seeking partnerships, biotechs should structure their narrative around three core questions pharma asks: What is the modality? How does the mechanism work? And most importantly, why is this the best differentiated approach to solve a specific clinical challenge and fit into the competitive landscape?

When evaluating revolutionary ideas, traditional Total Addressable Market (TAM) analysis is useless. VCs should instead bet on founders with a "world-bending vision" capable of inducing a new market, not just capturing an existing one. Have the humility to admit you can't predict market size and instead back the visionary founder.

Early-stage biotech investing is less about quantitative analysis, as companies lack cash flow for traditional valuation. The primary skill is identifying founders who lack deep domain expertise, citing Y Combinator founders who didn't understand the CPT billing codes their company was based on.